Cytomed Therapeutics LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Choo Chee Kong, Chairman and Director of CytoMed Therapeutics Ltd, has amended his Schedule 13D filing to report beneficial ownership of 2,899,746 Ordinary Shares, representing 24.30% of the company's outstanding stock.
NASDAQ
SCHEDULE: CytoMed Chairman Boosts Stake to 22.05%
CytoMed Therapeutics Limited's Chairman, Choo Chee Kong, has increased his beneficial ownership to 22.05% of the company's ordinary shares.
NASDAQ
CytoMed Therapeutics Ltd's Chairman and Director, Choo Chee Kong, has filed an amended Schedule 13D, revealing a reduction in his beneficial ownership to 23.17% following a gift of 715,000 ordinary shares.